The scleral buckling procedures. I. Surgical techniques and management.
C L SCHEPENS, I D OKAMURA, R J BROCKHURST
https://pubmed.ncbi.nlm.nih.gov/13478226/Actively Recruiting
Led by Cincinnati Eye Institute, Southwest Ohio · Updated on 2026-10-29
860
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating methotrexate to prevent proliferative vitreoretinopathy PVR after primary surgery for rhegmatogenous retinal detachment. PVR is a complication that can cause retinal detachment to recur and lead to poor visual outcomes. This study is a phase 2, randomized, double-masked clinical trial conducted at the Cincinnati Eye Institute, aiming to find effective strategies to reduce PVR, which currently lacks proven preventive medication. Participants are randomly assigned to one of four groups receiving no methotrexate, receiving methotrexate only by postoperative injections at weeks 1, 3, 6, and 10, receiving methotrexate only by intraoperative infusion during surgery, or receiving both intraoperative infusion and postoperative injections. The intraoperative infusion involves methotrexate mixed into the balanced salt solution used during surgery, and injections are given into the eye. Sham injections are used for masking. The study compares these approaches to assess which may best prevent PVR. Participants will undergo 11 visits over about 12 months, including screening, surgery, and multiple postoperative assessments. Visual acuity, intraocular pressure, eye examinations, presence of PVR or epitheliopathy, and any methotrexate side effects will be monitored. Pregnancy screening and contraception discussions occur when appropriate. Researchers will measure outcomes such as PVR incidence, need for reoperations, visual acuity, and treatment-related complications to evaluate methotrexates role in preventing PVR after retinal detachment surgery.
CONDITIONS
Prevention of ProliFerative Vitreoretinopathy With Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
C
Christopher Riemann, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cincinnati Eye Institute, Southwest Ohio
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Methotrexate Injection | Methotrexate Infusion | Combined Methotrexate Infusion/Injection | Sham Injection (Control Group) |
|---|---|---|---|---|
| What it is | Injection of methotrexate into the eye during vitrectomy surgery for retinal detachment repair. | Infusion of methotrexate during retinal detachment surgical repair. | Both methotrexate infusion and injection are performed during retinal detachment surgery. | A sham (placebo) injection is used during surgery, with no active methotrexate given. |
| Role in the trial | Evaluates whether injecting methotrexate reduces risk of developing proliferative vitreoretinopathy after surgery. | Assesses if infusing methotrexate during surgery helps prevent proliferative vitreoretinopathy. | Tests if combining infusion and injection of methotrexate further decreases PVR risk. | Serves as the placebo control for comparison with methotrexate strategies. |
| Primary use | To potentially prevent development of proliferative vitreoretinopathy after retinal detachment surgery. | To potentially prevent the formation of proliferative vitreoretinopathy postoperatively. | To test combined methotrexate delivery for prevention of PVR following retinal detachment repair. | Acts as a control to measure the effects of methotrexate treatments. |
| How it is given or performed | Methotrexate is injected into the eye during vitrectomy surgery. | Methotrexate is infused into the eye during the surgical procedure. | Methotrexate is both infused and injected into the eye within the surgical procedure. | A sham (inactive) injection is given during surgery. |
| Evidence status | Results for methotrexate injection in this prevention setting are not yet established. Clinical evidence is still being collected in this study. | Efficacy of methotrexate infusion for preventing PVR is not yet established in the trial. Study results are pending. | No established evidence yet on the efficacy of combined infusion/injection; the trial is ongoing to collect such data. | Sham injection acts as the trial control, with no disease-prevention effect expected. |
| Important limitations | This is an ongoing study. Long-term safety and effectiveness of methotrexate injection for this purpose are not yet known. | The long-term outcomes and side effects of methotrexate infusion in this setting are still under investigation. | The safety and outcomes of the combined methotrexate approach are not established; no results yet available. | As a placebo, this arm does not test methotrexate's effectiveness or active risks. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 1 to 2 weeks before surgery
Participants are screened for eligibility including eye exams, pregnancy testing if applicable, and informed consent before surgery.
1 visit
Duration - 1 day
Participants undergo retinal detachment repair surgery with random assignment to one of four groups receiving different methotrexate treatments or placebo.
1 visit (day of surgery)
Duration - 10 weeks
Participants receive scheduled methotrexate injections or sham injections at weeks 1, 3, 6, and 10 after surgery along with regular eye exams and monitoring for side effects and PVR.
4 visits
Duration - Up to 12 months after surgery
Participants have additional visits for eye exams and visual acuity checks up to 12 months after surgery to monitor outcomes and complications.
5 visits
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
C L SCHEPENS, I D OKAMURA, R J BROCKHURST
https://pubmed.ncbi.nlm.nih.gov/13478226/W F Rachal, T C Burton
https://pubmed.ncbi.nlm.nih.gov/420635/Ama Sadaka, Robert A Sisk, James M Osher...
https://pubmed.ncbi.nlm.nih.gov/27698550/Xian Zhou, Xianjin Zhou, Huimin Shi...
https://pubmed.ncbi.nlm.nih.gov/32397978/Ge Wang, Xiaoyan Peng
https://pubmed.ncbi.nlm.nih.gov/32850138/Vivek Pravin Dave, Avinash Pathengay, Stephen G Schwartz...
https://pubmed.ncbi.nlm.nih.gov/25382968/David Steel
https://pubmed.ncbi.nlm.nih.gov/24807890/Edwin S L Chan, Bruce N Cronstein
https://pubmed.ncbi.nlm.nih.gov/20197777/Himadri Choudhury, Animesh Jindal, Avinash Pathengay...
https://pubmed.ncbi.nlm.nih.gov/26150690/J C Pastor
https://pubmed.ncbi.nlm.nih.gov/9716190/Cincinnati Eye Institute, Southwest Ohio
Lead Sponsor